Skip to main content

Table 2 Adverse Effects

From: Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder

  Placebo N = 116 IR-MPH (tid) N = 102 OROS-MPH N = 67  
  N (%) N (%) N (%) Omnibus Statistic
Dry Mouth 5 (4) 22 (22) * 25 (37)*,$ χ2 (2) = 32.2, p < 0.001
Headache 30 (26) 22 (22) 24 (36) χ2 (2) = 4.2, p = 0.1
Decreased Appetite 4 (3) 11 (11) * 24 (36)*,$ χ2 (2) = 38.8, p < 0.001
GI Complaints 13 (11) 17 (17) 20 (29)*,$ χ2 (2) = 10.3, p = 0.006
Sleep Problems 6 (5) 14 (14) * 14 (21) * χ2 (2) = 10.5, p = 0.005
Moodiness 7 (6) 15 (15) * 12 (18) * χ2 (2) = 6.9, p = 0.03
Aches and Pains 13 (11) 7 (7) 9 (13) χ2 (2) = 2.1, p = 0.3
  1. *, p < 0.05 versus Placebo, $, p < 0.05 versus IR-MPH (tid)